S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ENLV Enlivex Therapeutics Ltd

1.08

0.00 (0.00%)

Feb 03 2025 - Closed

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

null

Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Enlivex Therapeutics Charts.

Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Enlivex Therapeutics Charts.

Enlivex Therapeutics Ltd News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 11 December 2024 (2 months ago) • Edgar (US Regulatory)

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Wednesday 11 December 2024 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 3 December 2024 (2 months ago) • Edgar (US Regulatory)

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday 3 December 2024 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 29 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 20 November 2024 (2 months ago) • Edgar (US Regulatory)

Enlivex Adopts Bitcoin Treasury Reserve Strategy
Wednesday 20 November 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Thursday 14 November 2024 (3 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 12 November 2024 (3 months ago) • Edgar (US Regulatory)

Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday 12 November 2024 (3 months ago) • GlobeNewswire Inc.

More Enlivex Therapeutics Ltd News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions